Disclosure
HAI summary · Not investment advice
Hanmi Pharmaceutical's 3Q 2026 consolidated revenue was KRW 377.4 billion, up 4.2% year over year but down 19.2% quarter over quarter; operating profit was KRW 37.8 billion, down 31.3% and 71.2%.
Commentary
AI commentary · Not investment advice
What happened
Hanmi Pharmaceutical released its preliminary consolidated results for the third quarter of 2026 (July 1 to September 30) through a fair disclosure filed on October 27, 2026. Revenue was KRW 377.4 billion, operating profit was KRW 37.8 billion, and net profit was KRW 14.0 billion.
In the company's terms
Against the same quarter a year earlier, revenue rose 4.2% from KRW 362.3 billion. Operating profit fell 31.3% from KRW 55.1 billion, and net profit fell 69.1% from KRW 45.4 billion. Against the previous quarter, revenue fell 19.2% from KRW 467.2 billion. Operating profit fell 71.2% from KRW 131.1 billion, and net profit fell 83.3% from KRW 84.1 billion.
What changes for shareholders
The filing lists a ratio to market capitalization of 8.1%.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist